Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency

Joseph A. Church, Heinz Leibl, Mark R. Stein, Isaac R. Melamed, Arye Rubinstein, Lynda C. Schneider, Richard L. Wasserman, Borislava G. Pavlova, Karl Birthistle, Marianne Mancini, Sandor Fritsch, Lisa Patrone, Kerry Moore-Perry, Hartmut J. Ehrlich, Joseph A. Church, Linda B. Ford, Roger H. Kobayashi, Dennis K. Ledford, Issac R. Melamed, James N. MoyArye Rubinstein, Lynda C. Schneider, Mark R. Stein, Dale T. Umetsu, Richard L. Wasserman

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency'. Together they form a unique fingerprint.

Medicine & Life Sciences